📊 EWTX Key Takeaways
Is Edgewise Therapeutics, Inc. (EWTX) a Good Investment?
Edgewise is a pre-revenue biotech company with significant cash burn ($42.5M operating outflow annually) and deteriorating losses (-$49M net income, -12.4% YoY worsening). While the balance sheet is fortified with $493.2M equity and minimal debt, the cash runway appears limited relative to burn rate, and no revenue generation is evident to justify operational losses.
Edgewise Therapeutics shows very strong balance-sheet quality, with $522.26M of equity, minimal debt, and exceptional liquidity ratios that materially reduce near-term financing stress. However, the business remains pre-revenue and deeply unprofitable, with $167.79M in net losses and negative free cash flow of $144.07M, so the fundamental case depends on future clinical and commercialization execution rather than current operating performance.
Edgewise Therapeutics, Inc. Key Strengths (EWTX)
- Fortress balance sheet with $493.2M stockholders equity and negligible debt ($59K)
- Excellent liquidity position with 22.61x current ratio providing operational flexibility
- Minimal financial leverage risk with debt-to-equity ratio near zero
- Very strong liquidity with 19.85x current and quick ratios
- Low financial leverage with essentially no long-term debt
- Large equity base and cash resources support ongoing R&D investment
EWTX Stock Risks: Edgewise Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no commercial product generating income
- Significant operating cash burn of $42.5M annually with only $33.2M cash on hand
- Deteriorating EPS performance (-12.4% YoY), indicating worsening financial position
- Negative operating cash flow of -$42.8M free cash flow indicates cash runway concerns absent capital raise
- No revenue base, making growth quality and operating leverage unproven
- Large recurring losses and cash burn could require future capital raises if development timelines slip
- Negative returns on assets and equity indicate weak current capital efficiency
Key Metrics to Watch
- Quarterly cash burn rate relative to cash reserves - critical for runway analysis
- Clinical trial progression and regulatory milestones that could support future revenue potential
- Capital raising activity and equity issuances - necessary to extend cash runway
- Quarterly operating cash burn and ending cash balance
- Revenue emergence or clinical milestones that improve commercialization visibility
Edgewise Therapeutics, Inc. (EWTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.61x current ratio provides a solid financial cushion.
EWTX Profit Margin, ROE & Profitability Analysis
EWTX vs Healthcare Sector: How Edgewise Therapeutics, Inc. Compares
How Edgewise Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edgewise Therapeutics, Inc. Stock Overvalued? EWTX Valuation Analysis 2026
Based on fundamental analysis, Edgewise Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edgewise Therapeutics, Inc. Balance Sheet: EWTX Debt, Cash & Liquidity
EWTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edgewise Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.57 indicates the company is currently unprofitable.
EWTX Revenue Growth, EPS Growth & YoY Performance
Edgewise Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
EWTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edgewise Therapeutics, Inc. (CIK: 0001710072)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EWTX
What is the AI rating for EWTX?
Edgewise Therapeutics, Inc. (EWTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EWTX's key strengths?
Claude: Fortress balance sheet with $493.2M stockholders equity and negligible debt ($59K). Excellent liquidity position with 22.61x current ratio providing operational flexibility. ChatGPT: Very strong liquidity with 19.85x current and quick ratios. Low financial leverage with essentially no long-term debt.
What are the risks of investing in EWTX?
Claude: Pre-revenue stage with no commercial product generating income. Significant operating cash burn of $42.5M annually with only $33.2M cash on hand. ChatGPT: No revenue base, making growth quality and operating leverage unproven. Large recurring losses and cash burn could require future capital raises if development timelines slip.
What is EWTX's revenue and growth?
Edgewise Therapeutics, Inc. reported revenue of N/A.
Does EWTX pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
Where can I find EWTX SEC filings?
Official SEC filings for Edgewise Therapeutics, Inc. (CIK: 0001710072) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EWTX's EPS?
Edgewise Therapeutics, Inc. has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is EWTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Edgewise Therapeutics, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is EWTX stock overvalued or undervalued?
Valuation metrics for EWTX: ROE of -9.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is EWTX's AI grade for 2026?
Our dual AI analysis gives Edgewise Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EWTX's free cash flow?
Edgewise Therapeutics, Inc.'s operating cash flow is $-42.5M, with capital expenditures of $260.0K.
How does EWTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.9% (avg: 15%), current ratio 22.61 (avg: 2).